Isolation & Characterization of Phytochemicals with Insulin-releasing or Glucose Lowering Effects for the Treatment of Type-2 Diabetes - Research
Summary
Before the discovery of insulin in 1922, diets and plant-based treatments were the common approaches to diabetes therapy. In addition to metformin that was developed from a Galega officinalis, research evidence is being increasingly published to show that many plant derived bioactive compounds have the potential for development into drugs for treating type-2 diabetes. Previous studies in our laboratory have also provided research evidence for the potential of extracts of some plant species as candidates for development into antidiabetic agents. Recently, we isolated a number of insulinotropic compounds from the extracts and these compounds exhibited potent in vitro insulin-releasing effects on BRIN-BD11 cells. They also improved glucose tolerance and enhanced insulin release in animals with obesity-diabetes on a short-term basis.
The overall aim of this research is structural characterization and evaluation of biological activities of compounds recently isolated from extracts of traditional antidiabetic plant for potential development as novel type 2 diabetes drugs. It may also be possible to incorporate into the project other plant species with reputed antidiabetic properties depending on the interests of the applicant.
The proposed research will provide training in a wide range of techniques including RP-HPLC, NMR, Ultrasound-assisted sequential extraction, Thin Layer Chromatography (TLC), Flash Chromatography, MALDI-TOF mass spectrometry; tissue culture; measurement of insulin secretion, signaling molecules (intracellular Ca2+ and other second messenger pathways); peptide iodination, cell morphology; ELISA; RIA; short studies in animal of obesity-diabetes.
Established collaborations are in place for structural characterization and large-scale purification of plant materials. This research will generate novel IP, high quality publications and potential exploitation through pharmaceutical development.
Applicants should note that Bench fees of £6,000.00-£8,000.00 per annum are required.
Entry requirements
Essential criteria
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
- Sound understanding of subject area as evidenced by a comprehensive research proposal
- A comprehensive and articulate personal statement
Desirable Criteria
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
- First Class Honours (1st) Degree
- Completion of Masters at a level equivalent to commendation or distinction at Ulster
- Practice-based research experience and/or dissemination
- Experience using research methods or other approaches relevant to the subject domain
- Work experience relevant to the proposed project
- Publications record appropriate to career stage
- Experience of presentation of research findings
Application dates
Submission Deadline: Sunday 1st September 2024 12:00am.
How to Apply
We are delighted that you are considering Ulster University for your research studies.
Get full details on the application process and further guidance on how to apply, and what you will need to upload as part of your application (see "Application Date Weblink").
Once you have identified supervisors, discussed a research proposal and are ready to make an application, please apply using the online application system (see "Application Weblink").
Ulster University welcomes applications from all sections of the community and from persons with disabilities. It is University policy to assess all applications using academic criteria and on the basis of equality of opportunity and you should be assured that reasonable adjustments will be made should you require them.